A5033507037- Multiple Sclerosis Research Studies
- Neutrino Physics Research
- Cancer survivorship and care
- Acute Lymphoblastic Leukemia research
- Astrophysics and Cosmic Phenomena
- Chronic Disease Management Strategies
- Particle physics theoretical and experimental studies
- Health Systems, Economic Evaluations, Quality of Life
- Dark Matter and Cosmic Phenomena
- Palliative Care and End-of-Life Issues
- Cancer Risks and Factors
- Polyomavirus and related diseases
- Frailty in Older Adults
- Peripheral Neuropathies and Disorders
- Rheumatoid Arthritis Research and Therapies
- Breast Cancer Treatment Studies
- Mycobacterium research and diagnosis
- Pneumonia and Respiratory Infections
- Lymphadenopathy Diagnosis and Analysis
- Metabolism, Diabetes, and Cancer
- Viral Infections and Immunology Research
- Advanced Causal Inference Techniques
- Reproductive System and Pregnancy
- Advanced Breast Cancer Therapies
- Chemotherapy-induced cardiotoxicity and mitigation
Flinders University
2022-2025
SA Health
2024-2025
Flinders Medical Centre
2022-2025
Community Care
2025
University of British Columbia
2001-2024
Nova Scotia Health Authority
2022-2024
Dalhousie University
2022-2024
University of Manitoba
2022-2024
Saskatchewan Health Quality Council
2022-2024
University of Saskatchewan
2022-2024
It is not possible to fully establish the safety of a disease-modifying drug (DMD) for multiple sclerosis (MS) from randomized controlled trials as only very common adverse events occurring over short-term can be captured, and quality reporting has been variable. We examined relationship between DMDs MS potential in multiregion population-based study.
Abstract Aim To assess the prevalence of comorbidities and measures physical mental health among cancer patients survivors compared with general population. Methods Data collected by Australian Bureau Statistics from 2011–2012 National Health Survey were utilized for this cross‐sectional study. Comparisons made between adults aged 25 years over history ( n = 2170) those respondents who did not report having had a 11 592) using logistic regression models. Analyses repeated according to status...
Pneumonia is associated with considerable mortality.However, there limited information on agespecific prognostic factors for death from pneumonia.METHODS Patients hospitalised a diagnosis of pneumonia through the emergency department were stratified into three age groups: 18-64 years, 65-84 years and ≥ 85 years.Multivariate logistic regression receiver operating characteristic curve analyses conducted to evaluate mortality performance severity scoring tools prediction.RESULTS A total 1,902...
ObjectiveIn long-term follow-up studies, individuals often experience multiple types of events. Standard survival models focus on just one type, limiting the scope analysis. In contrast, multi-state investigate event simultaneously. Multi-state models, though straightforward to implement, are not common in clinical studies. This article demystifies modelling and demonstrates helpful techniques for studies.Study Design SettingA case study (1996–2017) 9,124 with sclerosis illustrates several...
Background Most older patients with atrial fibrillation (AF) have comorbidities. However, it is unclear whether specific comorbidity patterns are associated adverse outcomes. We identified and their association mortality in multimorbid AF different multidimensional frailty.
Abstract Background Dementia is a prevalent condition in an ageing population. Persons with dementia and their caregivers are often uncertain about what to expect after initial diagnosis. Previous studies conducted on the experiences of informal show clear demand address these: providing adequate information, psychosocial support access services. Introduction The diagnosis usually made by specialists hospital. Resources acute tertiary hospital valuable need be carefully distributed. To...
ABSTRACT Purpose Given the historical use of limited confounders in multiple sclerosis (MS) studies utilizing administrative health data, this brief report evaluates impact incorporating high‐dimensional proxy information on confounder adjustment MS research. We have implemented propensity score (hdPS) and disease risk (hdDRS) methods to assess changes effect estimates for association between disease‐modifying drugs (DMDs) all‐cause mortality an cohort from British Columbia (BC), Canada....
Background: Little is known about polypharmacy and multiple sclerosis (MS). Objectives: To estimate prevalence in a population-based MS cohort compare persons with/without polypharmacy. Methods: Using administrative pharmacy data from Canada, we estimated (⩾5 concurrent medications for >30 consecutive days) individuals 2017. We compared the characteristics of described number days, most common medication classes contributing to hyper-polypharmacy (⩾10 medications). Results: Of 14,227...
Background: The relationship between socioeconomic status (SES) and mortality among persons with multiple sclerosis (PwMS) is poorly understood. Objective: To investigate the association SES risk in PwMS. Methods: From health-administrative data, we identified 12,126 incident MS cases a first demyelinating event (MS ‘onset’) occurring 1994 2017. Cox proportional hazard model assessed quintiles (SES-Qs) at onset all-cause mortality. Results: Lower SES-Qs were associated higher risk; adjusted...
We examined the association between disease-modifying drugs (DMDs) for multiple sclerosis (MS) and survival in a multiregion population-based study.We accessed administrative health databases from 4 Canadian provinces. Persons with MS were identified followed most recent of first or demyelinating event January 1, 1996 (index date), until death, emigration, December 31, 2017. Association first-generation second-generation DMDs all-cause mortality was using stratified Cox proportional hazard...
To compare how frequently selected chronic diseases developed in women with breast cancer receiving endocrine therapy, and without cancer.Retrospective, rolling cohort study, analysing a random 10% sample of Pharmaceutical Benefits Scheme (PBS) data for the period 1 January 2003 - 31 December 2014. Women who first commenced therapy between 2004 2011 were identified, age- sex-matched (1:10) by comorbidity control groups did not have dispensing record antineoplastic agents during study or...
Background Evidence regarding the efficacy or effectiveness of disease-modifying drugs (DMDs) in older multiple sclerosis (MS) population is scarce. This has contributed to a lack evidence-based treatment recommendations for ageing MS practice guidelines. We examined relationship between age (<55 and ≥55 years), DMD exposure health service use population. Methods conducted population-based observational study using linked administrative data from British Columbia, Canada. selected all...
The belief that all new medicines bring a therapeutic innovation and better health outcomes is widely shared among the public, professionals policy makers.To examine value of marketed in Australia using two classification systems.The was categorised Motola's s Ahlqvist-Rastad's systems for approvals made by Australian Therapeutics Goods Administration (TGA) between 2005 2007. Scores were assigned independently three authors on basis Public Summary Documents Prescrire' review...
A prospective observational study was conducted in a cohort of older adults ≥65 years (n = 329), admitted to the acute medical unit (AMU) tertiary hospital, describe and compare characteristics including frailty status clinical outcomes. Multivariable models compared with without history cancer determine associated pre-frailty. An adjusted Poisson regression model used length hospital stay (LOS) between two groups. About one-fifth (22%) had cancer. The most common types were prostate 20),...
The development of comorbidities has become increasingly relevant with longer-term cancer survival.To assess the pattern among Australian women breast treated tamoxifen or an aromatase inhibitor.Retrospective cohort study using Pharmaceutical Benefits Scheme (PBS) data (10% sample) from January 2003 to December 2014. Dispensing claims were used identify and classified Rx-Risk-V model. had inhibitor dispensed between 2004 2011 no switching types endocrine therapy. Comparisons made specific...
Background: Relatively little is known about the use of disease-modifying drugs (DMDs) for multiple sclerosis (MS) in population-based universal healthcare setting. This study aimed to describe characteristics a cohort with MS and their DMD exposure four Canadian provinces. Methods: We identified all adults (aged ≥18 years) using linked health administrative data. Individuals were followed from most recent first or demyelinating event 1 January 1996(study entry), earliest death, emigration,...